Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study

Hamilton, E; Shapiro, CL; Petrylak, D; Boni, V; Martin, M; Del Conte, G; Cortes, J; Agarwal, L; Arkenau, HT; Tan, AR; Debruyne, P; Minchom, A; Rutten, A; Valdes-Albini, F; Yu, EY; Augustine, B; D'Amelio, A; Barrios, D; Hurvitz, SA

CANCER RESEARCH, 2021; 81 (4):

科室
- - 订阅+
  - 更多科室
工具
服务